New directions to develop therapies for people with hemophilia.

Gogia, Pooja; Tarantino, Michael; Schramm, Wolfgang; Aledort, Louis

Gogia, Pooja; Tarantino, Michael; Schramm, Wolfgang; Aledort, Louis.

Afiliação

Gogia P; Division of Hematology/Oncology, Maimonides Medical Center, Brooklyn, NY, USA.
Tarantino M; University of Illinois College of Medicine, and the Bleeding and Clotting Disorders Institute, Peoria, IL, USA.
Schramm W; Ludwig-Maximilians University (LMU) Rudolf Marx Stiftung Munich, München, Germany.
Aledort L; Division of Hematology/Oncology, Icahn School of Medicine, New York, NY, USA.

Expert Rev Hematol ; 16(6): 417-433, 2023 06.

Article em En | MEDLINE | ID: mdl-36891589

Assuntos

Hemofilia A; Hemofilia B; Humanos; Hemofilia A/terapia; Fator VIII/efeitos adversos; Meia-Vida; Hemofilia B/terapia; Fator IX/efeitos adversos

Palavras-chave

Hemophilia; extended halflife factor IX; extended halflife factor VIII; gene therapy; inhibitor; replacement factor IX; replacement factor VIII

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemofilia B / Hemofilia A Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google